Introduction
The field of oncology has witnessed remarkable advancements in immunotherapy, with monoclonal antibodies and bispecific antibodies leading the charge. Among these, odronextamab has emerged as a promising candidate for treating hematologic malignancies. This article explores the mechanism of action, clinical development, and potential impact of odronextamab in cancer therapy.
What Is Odronextamab?
Odronextamab is a bispecific antibody designed to simultaneously target CD20 on B cells and CD3 on T cells. By bridging these two immune cell types, odronextamab facilitates T-cell-mediated destruction of malignant B cells. This innovative approach enhances the body’s natural immune response against cancer, offering a novel treatment option for patients with relapsed or refractory B-cell malignancies.
